Remove 2015 Remove Small Molecule Remove Structure Based Drug Design (SBDD)
article thumbnail

Sosei Heptares scores $5m milestone payment from Pfizer

The Pharma Data

The collaboration has leveraged Sosei’s StaR technology and Structure-based Drug Design (SBDD) capabilities to design oral small molecules that modulate different G protein-coupled receptor (GPCR) targets across multiple disease areas. Source link.